Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension.
Oldham, William M
Cottrill, Katherine A
Vanderpool, Rebecca R
Vargas, Sara O
Wallace, W Dean
Ross, David J
Haley, Kathleen J
Waxman, Aaron B
Parikh, Victoria N
De Marco, Teresa
Hsue, Priscilla Y
Simon, Marc A
Norris, Karen A
Chan, Stephen Y
AffiliationUniv Arizona, Dept Med
MetadataShow full item record
PublisherAMER SOC CLINICAL INVESTIGATION INC
CitationVascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. 2016, 126 (9):3313-35 J. Clin. Invest.
RightsCopyright © 2016 American Society for Clinical Investigation
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractDysregulation of vascular stiffness and cellular metabolism occurs early in pulmonary hypertension (PH). However, the mechanisms by which biophysical properties of the vascular extracellular matrix (ECM) relate to metabolic processes important in PH remain undefined. In this work, we examined cultured pulmonary vascular cells and various types of PH-diseased lung tissue and determined that ECM stiffening resulted in mechanoactivation of the transcriptional coactivators YAP and TAZ (WWTR1). YAP/TAZ activation modulated metabolic enzymes, including glutaminase (GLS1), to coordinate glutaminolysis and glycolysis. Glutaminolysis, an anaplerotic pathway, replenished aspartate for anabolic biosynthesis, which was critical for sustaining proliferation and migration within stiff ECM. In vitro, GLS1 inhibition blocked aspartate production and reprogrammed cellular proliferation pathways, while application of aspartate restored proliferation. In the monocrotaline rat model of PH, pharmacologic modulation of pulmonary vascular stiffness and YAP-dependent mechanotransduction altered glutaminolysis, pulmonary vascular proliferation, and manifestations of PH. Additionally, pharmacologic targeting of GLS1 in this model ameliorated disease progression. Notably, evaluation of simian immunodeficiency virus-infected nonhuman primates and HIV-infected subjects revealed a correlation between YAP/TAZ-GLS activation and PH. These results indicate that ECM stiffening sustains vascular cell growth and migration through YAP/TAZ-dependent glutaminolysis and anaplerosis, and thereby link mechanical stimuli to dysregulated vascular metabolism. Furthermore, this study identifies potential metabolic drug targets for therapeutic development in PH.
NoteAuthors retain rights to present the work without prior permission in original, revised, adapted, or derivative form, provided that all such use is for personal or nonprofit (and noncommercial) benefit, is consistent with any employment agreement, and references the original publication citation. Examples: reproduction in nonprofit publications; lecture display (slides, overheads, or digitized media); hosting on personal or curriculum vitae-oriented websites; and inclusion in institutional and/or funding-body repositories.
VersionFinal published version
Sponsorsle Canceropole PACA; la Region PACA; le Conseil Departementale 06; I'INSERM; ARC; IBiSA; Conseil Departemental 06 de la Region PACA; NIH [HL096834, HL124021, P01-HL103455, R56-HL126525, R01-HL090339, HL61795, HL48743, HL108630, GM107618, HL007633, HL128802, HL121174]; American Heart Association; Ligue Nationale contre le Cancer; Fondation Bettencourt-Schueller; French National Research Agency [ANR-11-LABX-0028-01]; Association pour la Recherche sur le Cancer (ARC) [PJA20131200325]; Gilead Sciences, Inc.